Table 4.

MDA research agenda.

  • What is the optimal measure of disease activity in PsA?

  • Do MDA components all reflect the inflammatory process? Are they all needed or are there issues of overlap?

  • Does MDA correlate with inflammation (biomarker and imaging)?

  • What are the longterm effects of achieving MDA on structural progression?

  • Does MDA adequately capture the patient perspective on treatment targets?

  • What is the optimal treatment strategy for obtaining and maintaining MDA?

  • Are there any additional biomarkers for achieving MDA?

  • Does achieving MDA correlate with improved health-related quality of life?

  • Is MDA an appropriate measure of disease in patients with axial PsA?

  • MDA: minimal disease activity; PsA: psoriatic arthritis.